BioVie, Inc. Common Stock (BIVI) Stock Price
BIVIStock
$2.16+45.95%52W
Market Cap$18.25M
P/E—
PEG Ratio—
Div yield—
Beta0.74
BIVI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)60.87%
Price vs S&P 500 (4W)31.79%
VGM Score80.82
BIVI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q3 2025 | -$0.79 | -$0.98 | -24.05%(-$0.19) | |
| Q2 2025 | -$3.60 | -$11.05 | -206.94%(-$7.45) | |
| Q1 2025 | -$3.20 | -$1.50 | +53.13%(+$1.70) | |
| Q4 2024 | — | -$4.60 | — |
BIVI Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.13
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIVIBioVie, Inc. Common Stock | — | — | A | $2.16 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About BioVie, Inc. Common Stock
BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurological and liver diseases. Its lead program, NE3107, is advancing through Phase 3 clinical trials for mild to moderate Alzheimer's disease. BIV201 targets life-threatening complications of advanced liver disease, including cirrhosis from hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver injury.